logo

Inovio Pharmaceuticals Inc. (INO)



Trade INO now with
  Date
  Headline
9/17/2018 8:30:05 AM Inovio Pharma Develops Novel H3N2 Influenza DNA Vaccine; Provides Complete Protection Against Lethal Challenges
9/5/2018 8:01:37 AM Inovio Doses 1st Subject In Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection
9/4/2018 1:03:20 AM Inovio, GeneOne Dose First Patient In Phase 1 Study To Evaluate Preventive Vaccine Against Hepatitis C Infection
8/16/2018 8:02:27 AM Inovio Doses First Patient In Phase 1/2a Study Designed To Evaluate INO-5401
8/14/2018 8:04:17 AM Inovio Says First Participant Dosed With PENNVAX-GP In Randomized Clinical Trial
8/7/2018 4:08:28 PM Inovio Q2 Net Loss $6.6 Mln Or $0.08 Per Share
8/6/2018 8:06:29 AM Inovio Enters Partnership With AIDS Malignancy Consortium To Evaluate VGX-3100
6/27/2018 8:03:10 AM Inovio Announces Positive Phase 1 Results Of Collaborative Vaccine Study With INO-4700 Against MERS
6/21/2018 8:02:17 AM Inovio :dosed First Patient As Part Of Phase 1/2 Immuno-oncology Trial In Patients With Newly Diagnosed Glioblastoma
5/21/2018 8:02:21 AM Inovio Opens Phase 2 Trial For VGX-3100 In Third Indication To Treat HPV
5/17/2018 8:02:44 AM Inovio Pharma Demonstrates PSA Stabilizing Effect Of INO-5150 Immunotherapy In Phase 1b Study For Prostate Cancer
5/9/2018 4:07:31 PM Inovio Pharmaceuticals Q1 Loss/share $0.36 Vs. Loss $0.31 Year Ago
4/11/2018 8:03:22 AM Inovio To Receive Up To $56 Mln From CEPI To Advance DNA Vaccines Against Lassa Fever And MERS
3/20/2018 8:02:09 AM Inovio Closes License And Collaboration Agreement With ApolloBio To Commercialize VGX-3100 In Greater China